RATIONALE: New vaccine approaches are needed for Pseudomonas aeruginosa, which continues to be a major cause of serious pulmonary infections. Although Th17 cells can protect against gram-negative pathogens at mucosal surfaces, including the lung, the bacterial proteins recognized by Th17 cells are largely unknown and could be potential new vaccine candidates. OBJECTIVES: We describe a strategy to identify Th17-stimulating protein antigens of Pseudomonas aeruginosa to assess their efficacy as vaccines against pneumonia. METHODS: Using a library of in vitro transcribed and translated P. aeruginosa proteins, we screened for Th17-stimulating antigens by coculturing the library proteins with splenocytes from mice immunized with a live-attenuated P. aeruginosa vaccine that is protective via Th17-based immunity. We measured antibody and Th17 responses after intranasal immunization of mice with the purified proteins mixed with the Th17 adjuvant curdlan, and we tested the protective efficacy of vaccination in a murine model of acute pneumonia. MEASUREMENTS AND MAIN RESULTS: The proteins PopB, FpvA, FptA, OprL, and PilQ elicited strong IL-17 secretion in the screen, and purified versions of PopB, FpvA, and OprL stimulated high IL-17 production from immune splenocytes. Immunization with PopB, which is a highly conserved component of the type III secretion system and a known virulence factor, elicited Th17 responses and also enhanced clearance of P. aeruginosa from the lung and spleen after challenge. PopB-immunized mice were protected from lethal pneumonia in an antibody-independent, IL-17-dependent manner. CONCLUSIONS: Screening for Th17-stimulating protein antigens identified PopB as a novel and promising vaccine candidate for P. aeruginosa.
RATIONALE: New vaccine approaches are needed for Pseudomonas aeruginosa, which continues to be a major cause of serious pulmonary infections. Although Th17 cells can protect against gram-negative pathogens at mucosal surfaces, including the lung, the bacterial proteins recognized by Th17 cells are largely unknown and could be potential new vaccine candidates. OBJECTIVES: We describe a strategy to identify Th17-stimulating protein antigens of Pseudomonas aeruginosa to assess their efficacy as vaccines against pneumonia. METHODS: Using a library of in vitro transcribed and translated P. aeruginosa proteins, we screened for Th17-stimulating antigens by coculturing the library proteins with splenocytes from mice immunized with a live-attenuated P. aeruginosa vaccine that is protective via Th17-based immunity. We measured antibody and Th17 responses after intranasal immunization of mice with the purified proteins mixed with the Th17 adjuvant curdlan, and we tested the protective efficacy of vaccination in a murine model of acute pneumonia. MEASUREMENTS AND MAIN RESULTS: The proteins PopB, FpvA, FptA, OprL, and PilQ elicited strong IL-17 secretion in the screen, and purified versions of PopB, FpvA, and OprL stimulated high IL-17 production from immune splenocytes. Immunization with PopB, which is a highly conserved component of the type III secretion system and a known virulence factor, elicited Th17 responses and also enhanced clearance of P. aeruginosa from the lung and spleen after challenge. PopB-immunized mice were protected from lethal pneumonia in an antibody-independent, IL-17-dependent manner. CONCLUSIONS: Screening for Th17-stimulating protein antigens identified PopB as a novel and promising vaccine candidate for P. aeruginosa.
Authors: Shabaana A Khader; Guy K Bell; John E Pearl; Jeffrey J Fountain; Javier Rangel-Moreno; Garth E Cilley; Fang Shen; Sheri M Eaton; Sarah L Gaffen; Susan L Swain; Richard M Locksley; Laura Haynes; Troy D Randall; Andrea M Cooper Journal: Nat Immunol Date: 2007-03-11 Impact factor: 25.606
Authors: Gregory P Priebe; Rebecca L Walsh; Terra A Cederroth; Akinobu Kamei; Yamara S Coutinho-Sledge; Joanna B Goldberg; Gerald B Pier Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Manuela Raffatellu; Renato L Santos; David E Verhoeven; Michael D George; R Paul Wilson; Sebastian E Winter; Ivan Godinez; Sumathi Sankaran; Tatiane A Paixao; Melita A Gordon; Jay K Kolls; Satya Dandekar; Andreas J Bäumler Journal: Nat Med Date: 2008-03-23 Impact factor: 53.440
Authors: Salomé LeibundGut-Landmann; Olaf Gross; Matthew J Robinson; Fabiola Osorio; Emma C Slack; S Vicky Tsoni; Edina Schweighoffer; Victor Tybulewicz; Gordon D Brown; Jürgen Ruland; Caetano Reis e Sousa Journal: Nat Immunol Date: 2007-04-22 Impact factor: 25.606
Authors: Ying-Jie Lu; Jane Gross; Debby Bogaert; Adam Finn; Linda Bagrade; Qibo Zhang; Jay K Kolls; Amit Srivastava; Anna Lundgren; Sophie Forte; Claudette M Thompson; Kathleen F Harney; Porter W Anderson; Marc Lipsitch; Richard Malley Journal: PLoS Pathog Date: 2008-09-19 Impact factor: 6.823
Authors: Siobhán McClean; Marc E Healy; Cassandra Collins; Stephen Carberry; Luke O'Shaughnessy; Ruth Dennehy; Áine Adams; Helen Kennelly; Jennifer M Corbett; Fiona Carty; Laura A Cahill; Máire Callaghan; Karen English; Bernard P Mahon; Sean Doyle; Minu Shinoy Journal: Infect Immun Date: 2016-04-22 Impact factor: 3.441